WO2015108449A1 - Agent nootropique "pantocalcine" sous forme liquide - Google Patents
Agent nootropique "pantocalcine" sous forme liquide Download PDFInfo
- Publication number
- WO2015108449A1 WO2015108449A1 PCT/RU2015/000014 RU2015000014W WO2015108449A1 WO 2015108449 A1 WO2015108449 A1 WO 2015108449A1 RU 2015000014 W RU2015000014 W RU 2015000014W WO 2015108449 A1 WO2015108449 A1 WO 2015108449A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- acid
- liquid form
- pantocalcin
- trilon
- Prior art date
Links
- 229950001260 hopantenic acid Drugs 0.000 title claims description 24
- SBBDHANTMHIRGW-QMMMGPOBSA-N hopantenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCC(O)=O SBBDHANTMHIRGW-QMMMGPOBSA-N 0.000 title claims description 17
- 239000007788 liquid Substances 0.000 title abstract description 12
- 239000002664 nootropic agent Substances 0.000 title description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 230000001777 nootropic effect Effects 0.000 claims abstract description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 18
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 18
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 13
- 239000005711 Benzoic acid Substances 0.000 claims description 9
- 235000010233 benzoic acid Nutrition 0.000 claims description 9
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 159000000007 calcium salts Chemical class 0.000 claims description 6
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 6
- 239000007968 orange flavor Substances 0.000 claims description 6
- -1 Hopantenic acid calcium salt Chemical class 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 5
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims description 5
- 239000008297 liquid dosage form Substances 0.000 claims description 3
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 33
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract description 16
- 239000000126 substance Substances 0.000 abstract description 10
- 239000013543 active substance Substances 0.000 abstract description 9
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 abstract description 8
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 3
- 239000008177 pharmaceutical agent Substances 0.000 abstract description 2
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 31
- OVXZVDMCQPLHIY-QXGOIDDHSA-L calcium;4-[[(2r)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]butanoate Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCCC([O-])=O OVXZVDMCQPLHIY-QXGOIDDHSA-L 0.000 description 10
- 239000000203 mixture Substances 0.000 description 7
- 208000036626 Mental retardation Diseases 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000006188 syrup Substances 0.000 description 6
- 235000020357 syrup Nutrition 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 235000019658 bitter taste Nutrition 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 206010013911 Dysgeusia Diseases 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 2
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 description 2
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 201000006347 Intellectual Disability Diseases 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- JBNULYRBVMNPIS-OWJCAWTQSA-L calcium;4-[[(2r)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]butanoate;hydrate Chemical compound O.[Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCCC([O-])=O JBNULYRBVMNPIS-OWJCAWTQSA-L 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000001253 Diurnal Enuresis Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- OUHCLAKJJGMPSW-UHFFFAOYSA-L magnesium;hydrogen carbonate;hydroxide Chemical compound O.[Mg+2].[O-]C([O-])=O OUHCLAKJJGMPSW-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the invention relates to a pharmaceutical agent having nootropic properties of a mixed type with a wide spectrum of action, affecting the gamma-aminobutyric acid (GABA) system and can be used in medicine in neuropsychiatric practice and the pharmaceutical industry.
- GABA gamma-aminobutyric acid
- the invention provides the creation of a convenient liquid dosage form for pediatric psychiatry and neurology. In addition, it has greater bioavailability.
- Calcium hopantenate is used in children with mental deficiency, oligophrenia, with a delay in the development of speech, and also (in complex therapy, and sometimes independently) in epilepsy, especially with polymorphic seizures or small epileptic seizures.
- the nootropic drug piracetam is known, the first drug of this class, which is used in violation of learning and memory processes, cognitive functions, both in healthy individuals and, in particular, impaired in various diseases [T. A. Voronin, S. B. Seredinin. Expert. and wedge, pharmacology, 61 (4), 1998, pp. 3-8].
- the disadvantage of the drug is some limitations in its use: the drug is not used for young children (under 8 years old), in addition, the drug does not have an anticonvulsant effect and, moreover, increases the risk of convulsive readiness, which inhibits its use in the practice of treating patients with various paroxysmal conditions.
- Known pharmaceutical composition having a nootropic effect (RF patent JYS 2145213, IPC A61K9 / 20, publ. 10.02.2000) and containing the active substance, excipients and the shell. It contains gamma-aminobutyric acid as an active substance, sugar and lubricants as auxiliary substances, and the shell consists of basic magnesium carbonate, wheat flour and sugar in the following ratio of ingredients, wt.%: Core: gamma-aminobutyric acid - 84 - 94; sugar - 5 - 15; lubricants - 0.8 - 1; Shell: magnesium carbonate basic - 10
- Pantogam in tablet form - calcium salt of homopantothenic acid [Pantogam. Twenty years of experience in psychoneurology. - M.: 1111 "Patent", 1998].
- excipients magnesium hydroxycarbonate, calcium stearate, talc, potato starch.
- drugs are available only in the form of tablets of 0.25 and 0.5 g. With a daily dose for children of 0.75-3 g, children have to take 3 to 12 tablets per day, depending on age and diagnosis. Since the drug is taken by children from 2 months to 15 years, taking into account the medical indications of the drug, it can be difficult to administer the desired dose to young children, and sometimes older children. This is further complicated by the fact that the product itself has a bitter taste.
- the closest analogue is the PANTOGAM nootropic agent (RF patent JN ° 2177783, IPC ⁇ 61 ⁇ 9 / 08? Published: January 10, 2002) containing pantogam (calcium salt of hopantenic acid) and excipients, characterized in that it is a syrup and as auxiliary substances contains glycerin, sorbitol, citric acid, aspartame, aromatic essence, sodium benzoate in the following ratio, May. %:
- Aromatic essence - 0.05 - 0.15;
- the disadvantages of this composition include the relatively low content of the active substance (not more than 20%), which requires oral administration several times a day, and liquid the syrup form of the drug has a high viscosity, which complicates the dosage of the drug and limits its use: for children from 3 years of age and older.
- the above-mentioned PANTOGAM prototype drug is produced by PIK-PHARMA LLC, in which the content of the active substance of pantogam does not exceed 10 wt.% Due to the fact that with an increase in the content of pantogam in syrup above 10 wt.%, Its organoleptic properties deteriorate that does not allow the use of the drug for children.
- the technical result of the invention is a dosage form of hopantenate in drops; increasing the content of the active substance in the liquid form of the drug (up to 40%) by improving its organoleptic properties and making it possible to reduce the viscosity of the liquid form of the drug by reducing the content of substances that increase its viscosity and increase the water content.
- Hopantenic acid calcium salt 21 0-41, 0
- Drops are a liquid form of a drug dissolved in water or another solvent, dosed in drops.
- Syrup is a liquid form of a drug dissolved in concentrated carbohydrate syrup. Concentrated syrup is used to improve the organoleptic properties of the drug.
- the solution of the drug has a sharp unpleasant taste with a pronounced bitter aftertaste.
- Trilon B substance in the composition of the preparation at the concentrations indicated in the application blocks the bitterness receptors and eliminates the bitter aftertaste.
- Trilon B into the composition of the drug fundamentally changed the organoleptic properties of the drug in the direction of improving its palatability without a significant change in viscosity. Moreover, in addition to changing the “intensity” of a sharp taste, the introduction of Trilon B completely eliminated the bitter aftertaste (apparently, the sensation of bitterness of a highly concentrated pantocalcin solution is associated with the limited specificity of bitterness receptors, which leads to a response to the effect of concentrated substances that are not specific for them). Chromatography studies showed that all Trilon B was bound to calcium ions. A further increase in the concentration of Trilon B in the solution was not possible due to limitations on solubility. Nevertheless, the correctors introduced managed to obtain an acceptable taste of a 40% pantocalcin solution.
- Example 1 The composition of the drug "Pantocalcin, drops", wt.%:
- Example 2 The composition of the drug "Pantocalcin, drops", wt.%:
- Example 4 The technology of preparing a solution of the claimed drug.
- pantocalcin substance is introduced and it is dissolved with stirring.
- pantocalcin and 1M hydrochloric acid is charged and dissolved by stirring.
- the remaining components are loaded sequentially: orange flavor - dissolution; Trilon B - dissolution; sodium saccharin; dissolution; benzoic acid - dissolution.
- the claimed invention ensures the achievement of a technical result by increasing the content of the active substance in liquid form of the drug (up to 40%) by improving its organoleptic properties and providing the possibility of reducing the viscosity of the liquid form of the drug due to reducing the content of substances in it, increasing its viscosity and increasing the water content.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- General Preparation And Processing Of Foods (AREA)
Abstract
L'invention concerne un produit pharmaceutique possédant des propriétés nootropiques de type mixte à large spectre d'action d'action agissant sur le système d'acide gamma-aminobutyrique (GABA) et peut s'utiliser en médecine et dans la pratique psycho-neurologique ainsi qu'en industrie pharmaceutique. Le résultat technique de l'invention est une augmentation de sa teneur en forme liquide de préparation de la substance active (jusqu'à 40%) grâce à l'amélioration de ses propriétés organoleptiques et la possibilité de réduire la viscosité de la forme liquide de la préparation grâce à une moindre teneur en substances accroissant sa viscosité et grâce à l'augmentation de la teneur en eau.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EA201691206A EA027991B1 (ru) | 2014-01-20 | 2015-01-16 | Ноотропное средство "пантокальцин" в жидкой форме |
| CN201580005035.7A CN105979931A (zh) | 2014-01-20 | 2015-01-16 | 液体形式的益智药“pantocalcin” |
| UAA201607849A UA113822C2 (xx) | 2014-01-20 | 2015-01-16 | Ноотропний засіб в рідкій формі |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2014101564/15A RU2542419C1 (ru) | 2014-01-20 | 2014-01-20 | Ноотропное средсто "пантокальцин" в жидкой форме |
| RU2014101564 | 2014-01-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2015108449A1 true WO2015108449A1 (fr) | 2015-07-23 |
Family
ID=53289006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/RU2015/000014 WO2015108449A1 (fr) | 2014-01-20 | 2015-01-16 | Agent nootropique "pantocalcine" sous forme liquide |
Country Status (6)
| Country | Link |
|---|---|
| CN (1) | CN105979931A (fr) |
| EA (1) | EA027991B1 (fr) |
| MY (1) | MY180331A (fr) |
| RU (1) | RU2542419C1 (fr) |
| UA (1) | UA113822C2 (fr) |
| WO (1) | WO2015108449A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2703293C1 (ru) * | 2018-11-06 | 2019-10-16 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | Жидкая лекарственная форма для перорального введения, обладающая ноотропной активностью |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2145213C1 (ru) * | 1999-05-25 | 2000-02-10 | Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" | Фармацевтическая композиция, обладающая ноотропным действием, и способ ее получения |
| RU2177783C1 (ru) * | 2001-02-02 | 2002-01-10 | Общество С Ограниченной Ответственностью "Консорциум-Пик" | Ноотропное средство |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2181757C2 (ru) * | 2000-03-07 | 2002-04-27 | Тюменская государственная медицинская академия | Состав для стабилизации липидов |
| WO2008013197A1 (fr) * | 2006-07-26 | 2008-01-31 | Asahi Kasei Chemicals Corporation | Granulé brut sphérique et son procédé de fabrication |
-
2014
- 2014-01-20 RU RU2014101564/15A patent/RU2542419C1/ru active
-
2015
- 2015-01-16 UA UAA201607849A patent/UA113822C2/uk unknown
- 2015-01-16 EA EA201691206A patent/EA027991B1/ru unknown
- 2015-01-16 MY MYPI2016001359A patent/MY180331A/en unknown
- 2015-01-16 CN CN201580005035.7A patent/CN105979931A/zh active Pending
- 2015-01-16 WO PCT/RU2015/000014 patent/WO2015108449A1/fr active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2145213C1 (ru) * | 1999-05-25 | 2000-02-10 | Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" | Фармацевтическая композиция, обладающая ноотропным действием, и способ ее получения |
| RU2177783C1 (ru) * | 2001-02-02 | 2002-01-10 | Общество С Ограниченной Ответственностью "Консорциум-Пик" | Ноотропное средство |
Non-Patent Citations (1)
| Title |
|---|
| MASLOVA O.I. ET AL.: "Effektivnost primeneniya preparata Pantogam sirop 10% (gopantenovaya kislota) v korrektsii kognitivnykh rasstroistv u detei.", VOPROSY SOVREMENNOI PEDIATRII, vol. 3, no. 4, 2004, pages 2 - 6 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105979931A (zh) | 2016-09-28 |
| MY180331A (en) | 2020-11-28 |
| EA201691206A1 (ru) | 2016-09-30 |
| UA113822C2 (xx) | 2017-03-10 |
| RU2542419C1 (ru) | 2015-02-20 |
| EA027991B1 (ru) | 2017-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2938560T3 (es) | Formulaciones de cannabinoides estables | |
| JP2022169734A (ja) | 医薬溶液、調製方法及び治療的使用 | |
| US12128083B2 (en) | Lisinopril formulations | |
| EP3003384B1 (fr) | Solution orale contenant du chlorhydrate d'atomoxétine | |
| US20240024340A1 (en) | Compositions and Methods For Treating Migraine | |
| DK2838510T3 (en) | Atomoxetine solution | |
| WO2018111345A1 (fr) | Solution orale comprenant du chlorhydrate d'atomoxétine et procédés associés | |
| EP4221714A1 (fr) | Compositions liquides orales comprenant de la chlorpromazine | |
| JP3162709B2 (ja) | 抗ストレス、ストレス予防性及び向神経性作用の医薬調製物 | |
| IL276838A (en) | Oral formulation and suspension of an oncology drug | |
| RU2542419C1 (ru) | Ноотропное средсто "пантокальцин" в жидкой форме | |
| JPH0344324A (ja) | 性機能賦活剤 | |
| RU2177783C1 (ru) | Ноотропное средство | |
| EP2594266A1 (fr) | Compositions solides pharmaceutiques contenant des sels ibuprofènes | |
| CN111096948A (zh) | 一种拉科酰胺口服液及其制备方法 | |
| CN114786668B (zh) | 用于治疗抑郁症的环丝氨酸和锂的组合疗法 | |
| RU2703293C1 (ru) | Жидкая лекарственная форма для перорального введения, обладающая ноотропной активностью | |
| WO2017137767A1 (fr) | Formulation contre une maladie neurodégénérative contenant de l'apocynine et du paéonol | |
| RU2546300C1 (ru) | Композиция, обладающая действием на центральную нервную систему и ее применение | |
| US20150258197A1 (en) | Eutectic isometheptene mucate | |
| ES2864669T3 (es) | Agente profiláctico y terapéutico para el trastorno por déficit de atención/hiperactividad | |
| EP4338728A1 (fr) | Composition liquide de topiramate et son utilisation, procédé de fabrication d'une composition et kit | |
| CN100560582C (zh) | 哌啶基吡唑类化合物及其制法和应用 | |
| EA041149B1 (ru) | Жидкая лекарственная форма для перорального введения, обладающая ноотропной активностью |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15737777 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 201691206 Country of ref document: EA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: A201607849 Country of ref document: UA |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: IDP00201604828 Country of ref document: ID |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 15737777 Country of ref document: EP Kind code of ref document: A1 |